High-performance liquid chromatographic assay for the determination of nilotinib in human plasma

22Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

A precise and convenient high-performance liquid chromatography (HPLC) method has been established to assay nilotinib in human plasma. Chromatographic separation of nilotinib was performed on a LiChrosphere®100 RP-18(e) column (250 mm x 4.0 mm, 5 μm) using a mixture of acetonitrile and 0.01 M phosphate buffer (pH 3.0) (42 : 58, v/v) under isocratic conditions at a flow rate of 1.0 ml/min with ultraviolet (UV) detection at 266 nm. The calibration curve showed linearity at concentrations between 250 ng/ml and 5000 ng/ml (r 2>0.999). The mean±S.D. absolute recovery of nilotinib from plasma was 99.2±3.3%. The coefficients of variation of both intra- and inter-day precision were below 9.1%. These results indicate that this new HPLC-based quantification may be useful for therapeutic drug monitoring of nilotinib to help manage treatment in patients with chronic myeloid leukemia in clinical practice. © 2011 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Yuki, M., Yamakawa, Y., Uchida, T., Nambu, T., Kawaguchi, T., Hamada, A., & Saito, H. (2011). High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biological and Pharmaceutical Bulletin, 34(7), 1126–1128. https://doi.org/10.1248/bpb.34.1126

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free